{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:02:52Z","timestamp":1784538172634,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype in which neoadjuvant chemotherapy plays an important role in initial treatment. Pathological complete response (pCR) following neoadjuvant therapy can serve as a surrogate marker for long-term survival. Our study aimed to evaluate the value of the Pan-Immune-Inflammation Value (PIV), Neutrophil-to-Lymphocyte Ratio (NLR), and Platelet-to-Lymphocyte Ratio (PLR), measured at multiple time points, in predicting pCR. Methods: We retrospectively included 89 patients with non-metastatic TNBC treated with neoadjuvant chemotherapy with or without immunotherapy, followed by surgery. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Pan-Immune-Inflammation Value (PIV) were calculated at baseline, before the second treatment cycle, and at the pragmatic pre-transition assessment before a subsequent treatment phase, when applicable. The primary endpoint was pCR, defined as ypT0N0. Multivariable logistic regression models included age, Ki-67, clinical T stage, and tumor grade. Biomarker-extended models were compared with the clinical model on identical complete-case samples. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), likelihood ratio testing, calibration measures, Brier scores, and bootstrap internal validation with 2000 resamples. Results: pCR was achieved in 25 of 89 patients (28.1%). Baseline platelet counts were lower in patients with pCR than in those without pCR (median 246 \u00d7 103\/\u00b5L vs. 272 \u00d7 103\/\u00b5L; p = 0.021). At the pre-transition assessment, patients with pCR had lower monocyte counts (0.20 \u00d7 103\/\u00b5L vs. 0.57 \u00d7 103\/\u00b5L; p = 0.048) and lower PIVs (378.9 vs. 746.0; p = 0.011). Baseline PIV did not improve the clinical model. On the same 83-patient sample, adding baseline platelet count increased the apparent AUC from 0.751 to 0.807; however, the bootstrap 95% confidence interval (CI) for the AUC difference included zero (\u22120.003 to 0.128). On the same 75-patient sample, adding pre-transition PIV increased the apparent AUC from 0.735 to 0.798, with a bootstrap 95% confidence interval for the AUC difference of 0.005 to 0.142. The optimism-corrected AUC for the overall clinical model was 0.716, indicating lower internally validated performance than suggested by the apparent AUC. A smaller absolute increase in PIV from baseline to the pre-transition assessment was associated with pCR, but this finding was definition-dependent and remained exploratory. Conclusions: Standalone baseline markers have limited utility in predicting pCR in non-metastatic TNBC. Pre-transition PIV showed the most consistent incremental association with pCR beyond conventional clinical variables, whereas the added value of baseline platelet count was uncertain and baseline PIV provided no incremental benefit. Because of the retrospective design, limited sample size, treatment heterogeneity, and evidence of model optimism, these findings should be regarded as hypothesis-generating and require external validation.<\/jats:p>","DOI":"10.3390\/jcm15145614","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:54:13Z","timestamp":1784534053000},"page":"5614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic Assessment of Systemic Inflammatory Markers in Predicting Pathological Complete Response After Neoadjuvant Treatment in Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1585-3877","authenticated-orcid":false,"given":"Grzegorz J.","family":"St\u0119pie\u0144","sequence":"first","affiliation":[{"name":"Department of Oncological Physiotherapy, Medical University of Lodz, Paderewskiego 4, 93-509 Lodz, Poland"},{"name":"University Clinical Hospital No. 2 of the Medical University of Lodz, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Boguszewska-Byczkiewicz","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Nicolaus Copernicus Provincial Multispecialty Center for Oncology and Traumatology, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0459-0642","authenticated-orcid":false,"given":"Maria","family":"Wo\u0142yniak","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ry\u015b-Bednarska","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Nicolaus Copernicus Provincial Multispecialty Center for Oncology and Traumatology, 93-513 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0055-3273","authenticated-orcid":false,"given":"Thomas","family":"Wow","sequence":"additional","affiliation":[{"name":"Medical Practice Thomas Wow, 00-841 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Ko\u0142aci\u0144ska-Wow","sequence":"additional","affiliation":[{"name":"Department of Oncological Physiotherapy, Medical University of Lodz, Paderewskiego 4, 93-509 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast Cancer: Pathogenesis and Treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple Negative Breast Cancer: Pitfalls and Progress","volume":"8","author":"Zagami","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","article-title":"Molecular Classification of Breast Cancer: Relevance and Challenges","volume":"147","author":"Zhang","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-Negative Breast Cancer Has Worse Overall Survival and Cause-Specific Survival than Non-Triple-Negative Breast Cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.ajpath.2017.03.016","article-title":"The Spectrum of Triple-Negative Breast Disease","volume":"187","author":"Geyer","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early Breast Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lee, J. (2023). Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). J. Clin. Med., 12.","DOI":"10.3390\/jcm12041524"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/BCTT.S516125","article-title":"Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond","volume":"17","author":"Agelidis","year":"2025","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.6004\/jnccn.2020.7550","article-title":"Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer","volume":"18","author":"Huang","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2015.02.011","article-title":"Can Pathologic Complete Response (pCR) Be Used as a Surrogate Marker of Survival after Neoadjuvant Therapy for Breast Cancer?","volume":"95","author":"Chalabi","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-Analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez Abad, M., Calabuig-Fari\u00f1as, S., Lobo De Mena, M., Torres-Mart\u00ednez, S., Garc\u00eda Gonz\u00e1lez, C., Garc\u00eda Garc\u00eda, J.\u00c1., Iranzo Gonz\u00e1lez-Cruz, V., and Camps Herrero, C. (2022). Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. Cancers, 14.","DOI":"10.3390\/cancers14020307"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor Infiltrating Lymphocytes Are Prognostic in Triple Negative Breast Cancer and Predictive for Trastuzumab Benefit in Early Breast Cancer: Results from the FinHER Trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2\u2013Positive and Triple-Negative Primary Breast Cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.gendis.2022.07.024","article-title":"Targeting PD-1\/PD-L1 in Cancer Immunotherapy: An Effective Strategy for Treatment of Triple-Negative Breast Cancer (TNBC) Patients","volume":"10","author":"Kumar","year":"2023","journal-title":"Genes Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yan, X., Lv, Q., Wu, J., Fang, J., Peng, L., and Zhao, X. (2025). The Efficacy and Immune-Mediated Safety of PD-1\/PD-L1 Combined with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Meta-Analysis. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1635418"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104309","DOI":"10.1016\/j.critrevonc.2024.104309","article-title":"Clinical Characteristics Associated with Efficacy and Prognosis among Patients Treated with PD-1\/PD-L1 Inhibitors for Early-Stage Triple-Negative Breast Cancers: A Meta-Analysis","volume":"196","author":"Wei","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41523-024-00674-y","article-title":"Pathologic Complete Response after Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers","volume":"10","author":"Myers","year":"2024","journal-title":"npj Breast Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pavese, F., Capoluongo, E.D., Muratore, M., Minucci, A., Santonocito, C., Fuso, P., Concolino, P., Di Stasio, E., Carbognin, L., and Tiberi, G. (2022). BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making. Cancers, 14.","DOI":"10.3390\/cancers14194571"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chen, J.H., Addanki, S., Roy, D., Bassett, R., Kalashnikova, E., Spickard, E., Kuerer, H.M., Meas, S., Sarli, V.N., and Korkut, A. (2024). Monitoring Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Using Circulating Tumor DNA. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12689-6"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Truffi, M., Sottotetti, F., Gafni, N., Albasini, S., Piccotti, F., Morasso, C., Tibollo, V., Mocchi, M., Zanella, V., and Corsi, F. (2022). Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Cancers, 14.","DOI":"10.3390\/cancers14215287"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4048\/jbc.2019.22.e41","article-title":"The Role of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Predicting Neoadjuvant Chemotherapy Response in Breast Cancer","volume":"22","author":"Kim","year":"2019","journal-title":"J. Breast Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s12282-020-01096-x","article-title":"The Dynamic Change of Neutrophil to Lymphocyte Ratio Is Predictive of Pathological Complete Response after Neoadjuvant Chemotherapy in Breast Cancer Patients","volume":"27","author":"Dan","year":"2020","journal-title":"Breast Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e047957","DOI":"10.1136\/bmjopen-2020-047957","article-title":"Role of Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy: A Meta-Analysis","volume":"11","author":"Zhou","year":"2021","journal-title":"BMJ Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e26202","DOI":"10.1097\/MD.0000000000026202","article-title":"Prognostic Value of Platelet-to-Lymphocyte Ratio in Neoadjuvant Chemotherapy for Solid Tumors: A PRISMA-Compliant Meta-Analysis","volume":"100","author":"Long","year":"2021","journal-title":"Medicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7150\/jca.23367","article-title":"The Value of Neutrophil-to-Lymphocyte Ratio for Response and Prognostic Effect of Neoadjuvant Chemotherapy in Solid Tumors: A Systematic Review and Meta-Analysis","volume":"9","author":"Li","year":"2018","journal-title":"J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12029-020-00445-5","article-title":"Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?","volume":"52","author":"Anand","year":"2021","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.breast.2018.12.014","article-title":"Combination of Peripheral Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Is Predictive of Pathological Complete Response after Neoadjuvant Chemotherapy in Breast Cancer Patients","volume":"44","author":"Graziano","year":"2019","journal-title":"Breast"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13078","DOI":"10.1038\/s41598-020-69965-1","article-title":"Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients Who Received Neoadjuvant Chemotherapy","volume":"10","author":"Bae","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cuello-L\u00f3pez, J., Fidalgo-Zapata, A., L\u00f3pez-Agudelo, L., and V\u00e1squez-Trespalacios, E. (2018). Platelet-to-Lymphocyte Ratio as a Predictive Factor of Complete Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207224"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3747\/co.25.3888","article-title":"Neutrophil\u2013Lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer","volume":"25","author":"Chae","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1016\/j.clbc.2020.05.008","article-title":"Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-Analysis","volume":"20","author":"Cullinane","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chung, W.-S., Chen, S.-C., Ko, T.-M., Lin, Y.-C., Lin, S.-H., Lo, Y.-F., Tseng, S.-C., and Yu, C.-C. (2022). An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Cancers, 14.","DOI":"10.3390\/cancers14174170"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14662","DOI":"10.1038\/s41598-021-94184-7","article-title":"Low Pan-Immune-Inflammation-Value Predicts Better Chemotherapy Response and Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy","volume":"11","author":"Cubukcu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lin, F., Zhang, L.-P., Xie, S.-Y., Huang, H.-Y., Chen, X.-Y., Jiang, T.-C., Guo, L., and Lin, H.-X. (2022). Pan-Immune-Inflammation Value: A New Prognostic Index in Operative Breast Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.830138"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Guclu, T., Tanriverdi, O., Bayrakci, I., Demir, B., Colak, G., Kitapl\u0131, S., Alkan, A., Gokoz-Do\u011fu, G., Topaloglu, S., and Barutca, S. (2026). Integration of Ki67 and Pan-Immune-Inflammation Value (PIV) into a Predictive Nomogram for Pathologic Complete Response in Triple-Negative Breast Cancer: (Ki67 and Inflammation in Triple-Negative Breast Cancer). BMC Cancer, 26.","DOI":"10.1186\/s12885-026-15842-5"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bjorl.2020.09.015","article-title":"Prognostic Role of Neutrophil-to-Lymphocyte Ratio to Laryngeal Squamous Cell Carcinoma: A Meta-Analysis","volume":"88","author":"Zhao","year":"2022","journal-title":"Braz. J. Otorhinolaryngol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12957-024-03595-z","article-title":"Pan-Immune-Inflammation Value as a Novel Prognostic Biomarker for Digestive System Cancers: A Meta-Analysis","volume":"22","author":"Yu","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hou, S., Song, D., Zang, Y., Hao, R., Li, L., and Zhu, J. (2024). Prognostic Relevance of Platelet Lymphocyte Ratio (PLR) in Gastric Cancer Patients Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1367990"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhou, K., Cao, J., Lin, H., Liang, L., Shen, Z., Wang, L., Peng, Z., and Mei, J. (2022). Prognostic Role of the Platelet to Lymphocyte Ratio (PLR) in the Clinical Outcomes of Patients with Advanced Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.962173"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e43069","DOI":"10.1016\/j.heliyon.2025.e43069","article-title":"Pathologic Complete Response and Breast Cancer Survival Post-Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis of Real-World Data","volume":"11","author":"Antonini","year":"2025","journal-title":"Heliyon"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1158\/0008-5472.CAN-20-1792","article-title":"Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis","volume":"80","author":"Huang","year":"2020","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1200\/JCO.2014.55.2836","article-title":"Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients with Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies","volume":"32","author":"Berruti","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"0854","DOI":"10.34133\/research.0854","article-title":"PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer","volume":"8","author":"Zhang","year":"2025","journal-title":"Research"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/jtim-2025-0029","article-title":"CircPLK1 Upregulates ETS1 to Confer Anthracycline Resistance in Triple-Negative Breast Cancer","volume":"13","author":"Dai","year":"2025","journal-title":"J. Transl. Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.32604\/or.2025.068292","article-title":"Isoliquiritigenin Inhibits Triple-Negative Breast Cancer Progression via Targeting the IRF5\/SLC7A5\/IDO1-Mediated Tryptophan Metabolism Pathway","volume":"33","author":"Duan","year":"2025","journal-title":"Oncol. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:10:21Z","timestamp":1784535021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":47,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145614"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145614","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}